WO2003017934A3 - Folded monomers of the hiv-1 protease and methods of their use - Google Patents

Folded monomers of the hiv-1 protease and methods of their use Download PDF

Info

Publication number
WO2003017934A3
WO2003017934A3 PCT/US2002/026757 US0226757W WO03017934A3 WO 2003017934 A3 WO2003017934 A3 WO 2003017934A3 US 0226757 W US0226757 W US 0226757W WO 03017934 A3 WO03017934 A3 WO 03017934A3
Authority
WO
WIPO (PCT)
Prior art keywords
hiv
protease
dimerization
methods
monomers
Prior art date
Application number
PCT/US2002/026757
Other languages
French (fr)
Other versions
WO2003017934A2 (en
Inventor
John L Medabalimi
Rieko Ishima
Angela M Gronenborn
Original Assignee
Us Gov Health & Human Serv
John L Medabalimi
Rieko Ishima
Angela M Gronenborn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv, John L Medabalimi, Rieko Ishima, Angela M Gronenborn filed Critical Us Gov Health & Human Serv
Priority to AU2002327506A priority Critical patent/AU2002327506A1/en
Publication of WO2003017934A2 publication Critical patent/WO2003017934A2/en
Publication of WO2003017934A3 publication Critical patent/WO2003017934A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/503—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses
    • C12N9/506—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses derived from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention relates to defining regions critical for dimerization of HIV-1 protease and production of folded protease monomers that inhibit dimerization and function of the wild-type protease. The invention also relates to HIV-1 inhibitors targetting the regions critical for dimerization. There are provided methods for interfering with viral maturation in HIV patients using these folded monomers or their encoding nucleic acids. Also provided are methods for treating HIV in conjunction with other antiviral therapies and medications. Further, the present invention provides assays for measuring dimerization ability of retroviral proteases and for evaluating the viral infection, and methods of screening for agents capable of binding to HIV-1 protease at the areas critical for dimerization.
PCT/US2002/026757 2001-08-23 2002-08-23 Folded monomers of the hiv-1 protease and methods of their use WO2003017934A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002327506A AU2002327506A1 (en) 2001-08-23 2002-08-23 Folded monomers of the hiv-1 protease and methods of their use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31438801P 2001-08-23 2001-08-23
US60/314,388 2001-08-23

Publications (2)

Publication Number Publication Date
WO2003017934A2 WO2003017934A2 (en) 2003-03-06
WO2003017934A3 true WO2003017934A3 (en) 2003-12-24

Family

ID=23219758

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/026757 WO2003017934A2 (en) 2001-08-23 2002-08-23 Folded monomers of the hiv-1 protease and methods of their use

Country Status (2)

Country Link
AU (1) AU2002327506A1 (en)
WO (1) WO2003017934A2 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6165794A (en) * 1994-11-10 2000-12-26 The Regents Of The University Of California Suppression of proteolytic activity by dysfunctional protease formation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6165794A (en) * 1994-11-10 2000-12-26 The Regents Of The University Of California Suppression of proteolytic activity by dysfunctional protease formation

Also Published As

Publication number Publication date
AU2002327506A1 (en) 2003-03-10
WO2003017934A2 (en) 2003-03-06

Similar Documents

Publication Publication Date Title
AP1717A (en) Sulfonamide inhibitors of aspartyl protease.
WO2004096842A3 (en) Sars virus nucleotide and amino acid sequences and uses thereof
CY1109659T1 (en) MVA expressing modified HIV, GAG and POL genes of HIV
ATE377654T1 (en) UBIQUITIN LIGASE ASSAY
WO2002076939A3 (en) Cysteine protease inhibitors
MY137777A (en) Inhibitors of aspartyl protease
WO2005032487A3 (en) Angiotensin-converting enzyme-2 as a receptor for the sars coronavirus
WO2005056585A3 (en) Sars coronavirus s proteins and uses thereof
WO2000047551A3 (en) Inhibitors of aspartyl protease
WO2003087138A3 (en) Methods for identifying polypeptide factors interacting with rna
WO2003017934A3 (en) Folded monomers of the hiv-1 protease and methods of their use
WO2003060098A3 (en) Methods for identifying compounds which inhibit binding of nucleocapsid 7 protein to hiv-1 rna
IL156799A0 (en) Peptides having affinity for the gp120 viral protein and use thereof
WO2002090300A8 (en) Nucleic acids and proteins with thioredoxin reductase activity
WO2003000916A3 (en) Telomerase expression repressor proteins and methods of using the same
WO2002099387A3 (en) Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of hiv/aids
WO2007019532A3 (en) Peptide aptamers that bind to the rep proteins of ssdna viruses
WO2004071462A3 (en) Methods and compositions for treatment of viral infections based on tsg101-vps28 interaction
WO2002034909A3 (en) Engineered chimera of hiv protein fragments and uses thereof
WO2001077157A3 (en) Full-length gb virus c (hepatitis g virus) rna transcripts are infectious in primary cd4 positive t cells and methods of treating hiv
WO2004027066A3 (en) Chimeric recombinant protein and in vitro diagnosis of hiv
WO2001072825A3 (en) Apoptin-associating protein
WO2002053587A3 (en) Polypeptide inducing hiv-neutralising antibodies
WO2005121376A3 (en) Hiv variants showing a novel resistance mechanism against protease inhibitors, diagnostic assays for detecting the variant, and methods for identifying drugs effective against the resistant variant
DE50208000D1 (en) COMPLEX COMPOUNDS AND THEIR USE FOR THE POLYMERIZATION OF OLEFINES

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP